Clinicopathologic Features and Prognosis of Female Early Breast Cancer With HER2 Low Expression: A Propensity Score Matched Analysis

BACKGROUND: Metastatic breast cancer (MBC) patients with low expression of human epidermal growth factor 2 (HER2) have been proven to benefit from HER2 targeted therapy. We aimed to determine how HER2-low status affected survival and metastatic risk as well as how it affected pathological complete r...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Lanyi, Huang, Qiyuan, Guo, Rong, Zhu, Keying, Tang, Yiyin, Chen, Dedian, Huang, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Navigating Breast Health: From Screening to Survivorship
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676074/
https://www.ncbi.nlm.nih.gov/pubmed/38023289
http://dx.doi.org/10.1177/11795549231202463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676074/
https://www.ncbi.nlm.nih.gov/pubmed/38023289
http://dx.doi.org/10.1177/11795549231202463

Ejemplares similares